WP
BBIO icon

Woodline Partners’s BridgeBio Pharma BBIO Stock Holding History

Woodline Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.4M Buy
301,012
+100
+0% +$7.25K 0.08% 316
2025
Q4 		$23M Buy
300,912
+102,594
+52% +$6.73M 0.09% 284
2025
Q3 		$10.3M Sell
198,318
-1,506,482
-88% -$73.5M 0.05% 435
2025
Q2 		$73.6M Buy
1,704,800
+79,045
+5% +$2.87M 0.39% 47
2025
Q1 		$56.2M Sell
1,625,755
-585,766
-26% -$19.8M 0.37% 71
2024
Q4 		$60.7M Buy
2,211,521
+1,261,772
+133% +$32.6M 0.41% 55
2024
Q3 		$24.2M Buy
949,749
+179
+0% +$4.7K 0.2% 167
2024
Q2 		$24.1M Buy
949,570
+248,821
+36% +$6.8M 0.23% 140
2024
Q1 		$21.7M Buy
700,749
+410,749
+142% +$14M 0.2% 159
2023
Q4 		$11.7M Sell
290,000
-835,634
-74% -$25.1M 0.13% 211
2023
Q3 		$29.7M Buy
1,125,634
+835,634
+288% +$23.7M 0.35% 75
2023
Q2 		$4.99M Sell
290,000
-23,195
-7% -$349K 0.06% 290
2023
Q1 		$5.19M Buy
313,195
+216,896
+225% +$2.53M 0.07% 290
2022
Q4 		$734K Buy
+96,299
New +$922K 0.01% 565

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners's BBIO Position: Q1 2026 in Review

Woodline Partners increased its BridgeBio Pharma (BBIO) stake by 0.03% in Q1 2026, buying an estimated $7.25K and bringing the position to 301,012 shares worth $22.4M. The position accounts for 0.08% of the portfolio, ranked #316.

Woodline Partners first reported a position in BBIO in Q4 2022 and has held it in 14 quarters since. The position peaked at $73.6M in Q2 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Woodline Partners held 301,012 shares of BridgeBio Pharma worth $22.4M as of Q1 2026.
  • Woodline Partners bought 100 BridgeBio Pharma shares in Q1 2026, an estimated $7.25K.
  • BridgeBio Pharma made up 0.08% of Woodline Partners's portfolio in Q1 2026, its #316 holding.
  • Woodline Partners first reported a position in BridgeBio Pharma in Q4 2022 and has held it in 14 quarters since.
  • Woodline Partners's BridgeBio Pharma position peaked at $73.6M in Q2 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.